Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Undisclosed Pharmaceutical Company

BioCentury | Nov 8, 2022
Distillery Therapeutics

Tetravalent TREM2 agonist antibody for Alzheimer's

BioCentury | Nov 8, 2022
Distillery Therapeutics

CAR T cells for Aspergillus fumigatas fungal infection

BioCentury | Sep 8, 2018
Product Development

Data distribution

How TransCelerate’s clinical data sharing platforms are improving clinical development
BioCentury | Aug 10, 2018
Financial News

Sensyne proposes London IPO

BioCentury | Aug 7, 2018
Financial News

Sensyne proposes London IPO

BioCentury | Mar 7, 2018
Translation in Brief

Model perpetrators

How a new mathematical model can predict drug-drug interactions
BioCentury | Feb 6, 2018
Politics & Policy

EU court upholds EMA's decisions on transparency

BioCentury | Feb 3, 2017
Company News

Abilita deal

Items per page:
1 - 10 of 84